Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

R2 appears active in high-risk FL and MZL

Key clinical point: Lenalidomide plus rituximab demonstrated activity against relapsed or refractory follicular lymphoma and marginal zone lymphoma in the MAGNIFY trial.

Major finding: The overall response rate was 73% in the entire cohort, 63% in rituximab-refractory patients, and 51% in patients who were refractory to both lenalidomide and rituximab.

Study details: A phase 3b trial of 310 evaluable patients with relapsed/refractory follicular lymphoma (grade 1-3a) or marginal zone lymphoma.

Disclosures: The trial is sponsored by Celgene. The researchers reported financial relationships with Celgene and other companies.


Andorsky DJ et al. ASCO 2019, Abstract 7513.